COmpliance and efficacy in Mono and combination tablet study ATacand/Atacand plus - COMBAT
Study identifier:NIS-CKR-ATA-2007/2
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A prospective, non-interventional, observational, multi-center trial to evaluate compliance and efficacy in mono and combination treatment of Candesartan cilexetil(Atacand)/ Candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg(Atacand plus) in hypertension
Medical condition
hypertension
Phase
-
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
9000
Study type
Observational
Age
18 Years +
Date
Study Start Date: 01 Jun 2007
Primary Completion Date: 01 Aug 2008
Study Completion Date: 01 Aug 2008
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Hyunah Caroline Choi
AstraZeneca Korea
